Abbott Laboratories $ABT Shares Sold by Cypress Capital Group

Cypress Capital Group cut its position in Abbott Laboratories (NYSE:ABT) by 15.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 65,542 shares of the healthcare product maker’s stock after selling 12,216 shares during the period. Cypress Capital Group’s holdings in Abbott Laboratories were worth $6,729,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nia Impact Advisors LLC increased its holdings in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after buying an additional 79 shares during the period. Clayton Financial Group LLC lifted its stake in Abbott Laboratories by 1.4% during the 4th quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock valued at $779,000 after acquiring an additional 84 shares during the period. Jamison Private Wealth Management Inc. lifted its stake in Abbott Laboratories by 0.5% during the 4th quarter. Jamison Private Wealth Management Inc. now owns 15,854 shares of the healthcare product maker’s stock valued at $1,986,000 after acquiring an additional 85 shares during the period. Raleigh Capital Management Inc. boosted its holdings in shares of Abbott Laboratories by 3.9% in the 4th quarter. Raleigh Capital Management Inc. now owns 2,287 shares of the healthcare product maker’s stock valued at $287,000 after acquiring an additional 85 shares during the last quarter. Finally, Riggs Asset Managment Co. Inc. increased its stake in shares of Abbott Laboratories by 9.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock worth $140,000 after acquiring an additional 88 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction on Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of research reports. Argus decreased their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Daiwa Securities Group downgraded Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research report on Wednesday, April 22nd. Barclays reduced their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research note on Monday, April 20th. Stifel Nicolaus lowered their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, BTIG Research raised their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $118.61.

Abbott Laboratories Stock Up 2.4%

ABT stock opened at $103.13 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm’s fifty day moving average is $91.61 and its 200 day moving average is $101.33. The firm has a market cap of $179.63 billion, a PE ratio of 33.38, a P/E/G ratio of 2.00 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the prior year, the firm posted $1.26 earnings per share. The company’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.